Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine
Saved in:
Weinstein, Z.M., et al., Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine. Drug and Alcohol Dependence, vol. 170, January, 2017, p. 9-16.
Ref.
521942
Location:
SIIS Archivo (R.854)
Palabras clave:
Drogodependencias, Drogas ilegales, Opiáceos, Tratamiento médico, Programas de mantenimiento, Reducción de daños, Buprenorfina, Fármacos, Psicótropos, Retención, Efectos
Drogodependencias, Drogas ilegales, Opiáceos, Tratamiento médico, Programas de mantenimiento, Reducción de daños, Buprenorfina, Fármacos, Psicótropos, Retención, Efectos
Similar Items: Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine
- ANTIDEPRESSANT TREATMENT DOES NOT IMPROVE BUPRENORPHINE RETENTION AMONG OPIOID DEPENDENT PERSONS
- HOME VERSUS OFFICE BASED BUPRENORPHINE INDUCTIONS FOR OPIOID DEPENDENT PATIENTS
- Compliance with buprenorphine medication-assisted treatment and relapse to opioid use
- A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia
- EXPANDING TREATMENT CAPACITY FOR OPIOID DEPENDENCE WITH OFFICE BASED TREATMENT WITH BUPRENORPHINE: NATIONAL SURVEYS OF PHYSICIANS
- Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's Office. Based Buprenorphine Pilot Program